Clinical trial
Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers
NCT00648336 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2003
- Completion date
- December 31, 2003
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy